79578-98-6Relevant articles and documents
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
-
Page/Page column 159, (2020/08/22)
The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and pharmaceutically acceptable slats thereof, pharmaceutical compositions comprising such compounds and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof.
Preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitor
-
Paragraph 0202-0207, (2019/05/08)
The invention discloses preparation and application of novel 4,6-disubstituted aminopyrimidine JAK (janus kinase) inhibitors, and provide drugs which can be used for preventing, treating and/or improving autoimmune diseases (for example, psoriasis, rheumatoid arthritis, inflammatory enteritis diseases, Jagren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), and have excellent JAK inhibitory activity. The invention also provides pharmaceutically acceptable composition containing the compounds and methods for preparing the compounds.
SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS
-
Paragraph 0857, (2019/07/13)
The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
Substitutive phenyl pyrimidine derivative as JAK kinase inhibitor or medicinal salt, preparation method and application thereof
-
Paragraph 0076; 0086; 0087; 0089; 0090, (2019/10/23)
The invention discloses a substitutive phenyl pyrimidine derivative as shown in a formula (I) as a JAK kinase inhibitor or medicinal salt, a preparation method and application thereof. The compound has excellent JAK inhibiting action and is used for preparing a drug for preventing, treating or improving autoimmune disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus and the like. The high activity JAK-3 inhibiting action IC50 shown by the compound can reach 1.7 n. The substitutive phenyl pyrimidine derivative is simple in synthetic route and high in implementation.
HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY
-
Paragraph 1084; 1086, (2015/11/16)
Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY
-
Paragraph 0280, (2015/06/25)
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof
-
Paragraph 0329; 0330, (2015/12/07)
A five-and-six-membered heterocyclic compound as represented by general formula I, pharmaceutically acceptable salt, metabolite, metabolic precursors or drug precursors thereof, preparation method, pharmaceutical composition, and use thereof; the five-and-six-membered heterocyclic compound has activity as a Janus kinase (JAK) inhibitor, and can be used to prepare drugs for treating diseases caused by the abnormal activity of kinase, such as cell proliferation diseases like cancer.
COMPOUNDS USEFUL AS CCR9 MODULATORS
-
Page/Page column 136; 137, (2015/07/15)
The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).
QUINOLINE AND ISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 103, (2012/03/26)
Provided herein are compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds a
QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 57, (2012/03/12)
Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
